{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Baseline, screening, positive, n=5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Baseline, screening, negative n=5"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Baseline, confirming, positive, n=0"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Baseline, confirming, negative, n=0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Baseline, negative, conclusive, n=5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 2, Day 1, screening, positive, n=4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 2, Day 1, screening, negative, n=4"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 2, Day 1, confirming, positive, n=0"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 2, Day 1, confirming, negative, n=0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 2, Day 1, negative, conclusive, n=4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 3, Day 1, screening, positive, n=2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 3, Day 1, screening, negative, n=2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 3, Day 1, confirming, positive, n=1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 3, Day 1, confirming, negative, n=1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 3, Day 1, negative, conclusive, n=2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"End of study, screening, positive, n=4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"End of study, screening, negative, n=4"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"End of study, confirming, positive, n=0"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"End of study, confirming, negative, n=0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"End of study, negative, conclusive, n=4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.","groups":[{"description":"Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (NHL)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 (Cycle 2, 3), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)","title":"Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)","type":"SECONDARY","unitOfMeasure":"Participants"}